Researchers have completed the final patient evaluations in a Phase 2 trial for a new drug called bezisterim, aimed at treating early-stage Parkinson’s disease. This trial, known as SUNRISE-PD, focused on understanding how bezisterim can help improve both motor and non-motor symptoms of the disease, which affects millions of people worldwide. The results from this trial are expected to be announced in the third quarter of 2026, potentially offering new hope for those living with Parkinson’s.

For individuals concerned about aging and maintaining their health, the findings from this trial could be significant. Parkinson’s disease is known for causing motor issues like tremors and stiffness, but it also leads to non-motor symptoms such as sleep disorders, anxiety, and cognitive decline. If bezisterim proves effective, it may help improve quality of life by addressing these diverse symptoms. The trial included 57 participants who had not yet received traditional treatments, which means the results could inform new approaches for early intervention.

The SUNRISE-PD trial is a small human study, which means that while the results are promising, they are not yet definitive. The trial was designed to gather data on how bezisterim affects various symptoms of Parkinson’s over a 20-week period, using a combination of clinical assessments and patient-reported outcomes. The study’s findings will contribute to the design of larger Phase 3 trials, which are necessary to confirm the drug’s effectiveness and safety for broader use.

As the results are anticipated later this year, people interested in Parkinson’s research should stay informed about the outcomes. While bezisterim’s potential is exciting, it’s important to remember that further studies will be needed to validate its benefits fully.

Source: globenewswire.com